3 results
The primary objective of the study is to demonstrate non-inferiority of the KineSpring System, when compared to standard HTO surgery in improving pain and function outcomes at 24 months in patients with primarily unicompartmental medial knee…
* To assess the safety and tolerability of Ampligen administered intranasally in a dosing schedule for 13 days (7 doses) in healthy subjects.* To characterize the mucosal immune response following Ampligen administration over time.
The primary objective of the safety run-in (phase Ib) is to determine the safety of combination therapy with durvalumab and rintatolimod. The primary objective of the phase II trial is to determine the clinical benefit rate of combination therapy…